This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Pharmaceutic innovation presented by Kazan University at Russian Venture Forum

April 15th, 2019 Kamill Gareev, Yury Nurmeev

The forum took place on 11th April in Kazan.

The showcase of the products was made by Head of Pharmaceutics Center Yury Shtyrlin. With Rector Ilshat Gafurov and guests present, he talked about eight prospective medications: anti-inflammatory, antibacterial, antifungal, antiseptic, antiepileptic, a preparation for the treatment of diabetes complications, and two antitumor compounds.

Four of them have passed preclinical trials, and now investment is needed for clinical stages – about 65 million rubles in each case. Two new medications – one for locomotor ailments and one antiseptic – are expected to be available in pharmacies in three to five years. Several foreign partners have shown interest.

Investment attractiveness was one of the main topics of the forum. 1,120 speakers and 649 companies joined the event this year.

Before the forum, the Workgroup for Science and Education of the State Council of Russia convened for a regular meeting at the same venue. Rector Gafurov contributed to the proceedings.

Kazan Federal University was commended as an example of successful innovation in education; in particular, KFU's IT Lyceum was mentioned in this context. President of Tatarstan Rustam Minnikhanov opined that our region has all the necessary tools to retain leadership in education and research.

Provided by Kazan Federal University

Citation: Pharmaceutic innovation presented by Kazan University at Russian Venture Forum (2019, April 15) retrieved 26 April 2024 from https://sciencex.com/wire-news/316759542/pharmaceutic-innovation-presented-by-kazan-university-at-russian.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.